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RESUMO
Objetivo: Realizar uma revisão sistemática com meta-análise sobre a eficácia da
trabeculectomia (TREC), seguida ou não por irradiação beta (BRT/TREC) para o tratamento
do glaucoma, em termos de controle da pressão intraocular (PIO) e de efeitos adversos,
em diferentes grupos étnicos.
Métodos: Uma meta-análise de ensaios clínicos randomizados (RCT) foi realizada,
comparando os resultados de 12 meses da TREC com o uso adjuvante de BRT, com aqueles
da TREC padrão. Foram fontes de pesquisa as bases de dados MEDLINE, EMBASE, LILACS,
Cochrane, além de sítios de registro de ensaios clínicos, estudos recentes em revistas da
área e outras bases de dados bibliográficos. Dois revisores avaliaram independentemen-
te publicações relevantes e as referências desses trabalhos foram pesquisadas para
procura de ensaios adicionais, de acordo com as diretrizes estabelecidas pelos critérios
do QUOROM.
Resultados: De um total de 1.350 citações, oito estudos (cinco coortes e três aleatori-
zados) foram identificados e apenas 3 RCT foram incluídos nesta meta-análise. Maiores
reduções na PIO foram verificadas no braço de estudo da BRT, comparado com o braço
controle (diferença média=1,68 mmHg, 95% CI= 0,61-2,68, P=0,002). A frequência de
PIO pós-operatória não controlada (>21 mmHg) foi menor quando utilizada a BRT
(BRT/TREC) em relação ao grupo controle (38/218 =17,4% versus 9/239 =3,8%; OR=
6,7 IC 95% 3,2 14,3, P<0,0001). Apesar do melhor controle da PIO ter sido observada em
todos os pacientes do braço BRT, apenas os pacientes negros apresentaram uma diferen-
ça significativa (P=0,005). Não houve diferenças significativas entre os braços BRT e
controle, em termos de perda da acuidade visual, complicações pós-operatórias e
necessidade de cirurgia de catarata.
Conclusão: O uso de BRT adjuvante aumenta a taxa de sucesso da TREC, com melhores
resultados em pacientes não-caucasianos, não influenciando a ocorrência de complica-
ções pós-operatórias.
Descritores: Glaucoma/cirurgia; Glaucoma/radioterapia; Trabeculectomia; Olho/efei-
tos de radiação; Partículas beta; Metanálise
ABSTRACT
Purpose: To conduct a systematic review with meta-analysis on the efficacy of
trabeculectomy (TREC) followed by beta irradiation (BRT/TREC) compared to TREC
alone for glaucoma in terms of intraocular pressure (IOP) control and adverse effects
of treatment in different ethnic groups.
Methods: A meta-analysis of randomized controlled trials (RCT) was performed
comparing adjunct BRT treatment for glaucoma with standard TREC after 12 months.
The MEDLINE, EMBASE, LILACS, and Cochrane Library databases, Trial registers,
bibliographic databases and recent studies of relevant journals were searched. Two
reviewers independently reviewed relevant reports and the references from these
reports were searched for additional trials, using guidelines set by QUOROM statement
criteria.
Results: Of a total of 1,350 citations, eight studies (five cohorts, three randomized)
were identified and only 3 RCT were included in this meta-analysis. Higher IOP
reductions were verified in the BRT arm compared to the control arm (mean diffe-
rence=1.68 mmHg, 95% CI= 0.61-2.68, P=0.002). Uncontrolled postoperative IOP
(>21 mmHg) was less frequent when BRT was used (BRT/ TREC arm) compared to the
control arm (38/218=17.4% versus 9/239=3.8%; OR=6.7; 95% CI 3.2-14.3, P<0.0001).
Although better IOP control was observed in all patients treated with adjuvant BRT,
only Black patients displayed a significant difference (P=0.005). There were no
significant differences between the BRT and control arms regarding loss of visual
acuity, postoperative complications and necessity of cataract surgery.
Conclusion: Adjunct BRT increases the success rate of TREC, with better results in
non Caucasian patients, and does not influence the occurrence of postoperative
complications.
Keywords: Glaucoma/radiation effects; Glaucoma/surgery; Glaucoma/radiotherapy;
Trabeculectomy; Eye/radiation effects; Beta particles; Meta-analysis
INTRODUCTION
Glaucoma is the world’s most common blinding condition cau-
sing irreversible visual loss(1). Strong evidence suggests that lowe-
ring intraocular pressure (IOP) is beneficial in reducing the deve-
lopment and progression of the disease(2,3). Trabeculectomy (TREC)
is the surgical procedure of choice to reduce IOP in patients with
glaucoma. However, TREC is not 100% successful in maintaining
adequate IOP control. A major cause of surgical failure is related to
fibroblast proliferation and scarring of the conjunctival bleb(4-6). In
patients at high risk for failure, adjuvant therapy aiming to inhibit
wound healing has been used. 5-fluorouracil (5-FU) or mitomycin C
(MMC) have been shown to be effective in increasing TREC success
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rate(7-13), however they have been associated with postoperative
complications, such as corneal epithelial defects, wound leak,
ischemic bleb, hypotony, blebitis, and endophthalmitis(4,5).
Beta radiation (BRT) is a particulate radiation consisting of high-
speed electrons, which are rapidly attenuated by biological tissues.
This makes it very useful for superficial radiation treatments where
deep tissue penetration is undesirable. Strontium-90 (90Sr), an
unstable fission product of uranium-235 (235U), has been found to
be a clinically useful source of beta radiation with a long half-life
(28.7 years), and emits only high-energy beta particles as it decays.
Among the emitters employed in ophthalmology, the 90Sr source
has the most marked attenuation in biological tissues, making it
particularly suitable for treatment of the ocular surface.
It has also been used as an auxiliary measure in some ocular
procedures, including in pterygium and in age-related macular de-
generation(6-11). BRT inhibits the proliferation of fibroblasts from the
Tenon’s capsule and the conjunctiva, both in vitro and in animal mo-
dels(5). The effectiveness and safety of adjunct BRT in glaucoma surgery
has not been adequately investigated because of small sample size,
variable radiation doses and mixed patient groups(6,14-20). Recently a
meta-analysis on this issue was published(21), however in this study
the authors did not evaluate the differences on IOP reduction among
races, adverse effects as hypotony, hyphema, bleb leak and choroidal
effusion. So, we decided to perform a systematic review and meta-
analysis in order to analyze the efficacy and safety of TREC followed
by beta irradiation (BRT/TREC) compared to TREC alone, including
potential differences between distinct ethnic groups.
METHODS
Criteria for considering studies for this systematic review were:
1. TYPES OF STUDIES
All randomized and quasi-randomized controlled trials were
eligible for inclusion.
2. TYPES OF PARTICIPANTS
Eligibility criteria were: adults with age of 40 years or more,
characteristic glaucomatous changes in the optic disc, IOP ≥21 mmHg
and open angle on gonioscopy. Trials with participants under 18
years old were not included. There were no restrictions regarding
gender or ethnicity.
3. TYPES OF INTERVENTION
All trials were included when TREC (without adjuvants) was
compared to BRT/TREC. All beta radiation emitters contained
strontium-90/yttrium-90b (strontium-90 decays to yttrium-90 on
release of the beta particle) in 8 mm disc applicator.
4. TYPES OF OUTCOME MEASURES
Main outcomes
The primary outcome measurement was surgical failure within
12 months, defined as IOP >21 mmHg with antiglaucoma medica-
tions. Secondary outcomes were visual acuity, mean IOP reduction,
surgical reintervention for cataract, and intraoperative and posto-
perative complications.
SEARCH STRATEGY FOR STUDIES IDENTIFICATION
The databases on MEDLINE (Ovid) (1996 to May 2007), BIOSIS
(1985 to July 2007) and CINAHL (1982 to August 2007), SIGLE,
ZETOC, NRR and http://www.controlled-trials.com were all searched
in February 2008 and revised in January 2011, using the terms:
“glaucoma” (Medical Subject Heading [MeSH]), “trabeculectomy”
(text word), “postoperative beta irradiation” (text words), “surgery
drainage” (text words) and “adjuvant radiotherapy” (MeSH and text
words). These terms were then combined with the search terms for
the following study designs: practice guidelines, systematic reviews
or meta-analyses, reviews, randomized controlled trials and con-
trolled clinical trials. References of all retrieved studies and reviews
were searched for additional trials. Manual searches in ophthal-
mology, journals or conference proceedings were not undertaken.
We did not contact pharmaceutical companies or manufacturers of
ophthalmic lasers and surgical equipment.
Two authors independently viewed the titles and abstracts of
all the studies identified in the electronic searches. All methodolo-
gical steps followed the guidelines set by QUOROM statement
criteria(22). The full copies of all possibly or definitely relevant studies
were obtained and independently inspected by two authors to
determine whether they met the inclusion criteria. When a diffe-
rence in opinion occurred, a third reviewer was consulted, as an
arbiter. The authors of the selected studies could be contacted to
elucidate any doubts, when necessary.
DATA ANALYSIS
Studies were examined as to whether the unit of randomization
was eyes or people. In all three included studies, the unit of rando-
mization was one eye per patient. Whenever possible, data were
extracted on the basis of an intention to treat analysis. Outcomes
were analyzed, when possible, in a stratified manner according to
short, medium and long-term outcome assessment. One author
entered the data into comprehensive meta-analysis and a second
author re-entered the data using the double-entry facility to check
errors and inconsistencies. IOP was analyzed as a continuous variable.
For each study, the mean IOP change from baseline, including the
standard deviation (SD) of change for each intervention group, was
calculated when possible. If the SD of change was not reported, it
was calculated assuming a correlation of 0.5 between the baseline
and end-point IOPs(23). When visual field and visual acuity outcomes
were reported as mean scores, data were analyzed as mean score
change from baseline and the SD of change. Visual field progres-
sion and visual acuity were analyzed when possible as categorical
variables. If reported as a score, the data were analyzed as conti-
nuous variables. If summary effect measures were reported, the lo-
garithm of the odds ratio (Ln OR) and the standard error (SE) were
entered into comprehensive meta-analysis as generic inverse
variance measures. When other studies presented similar outcomes
using proportions, the OR and the 95% confidence interval (95% CI)
were calculated. All meta-analyses were assessed for heteroge-
neity as a preliminary test. A random-effects model was used if the
test of heterogeneity was significant (P<0.05), otherwise a fixed-
effects model was used. An OR with a P value <0.05 was considered
statistically significant. Publication bias was assessed with the Begg
funnel plot and Egger weighted regression for funnel plot asym-
metry. Publication bias was considered significant if the Egger test
was significant (P<0.05) and the Begg plot suggested bias(24-26). Our
statistical analysis was performed with comprehensive meta-
analysis software (Comprehensive Meta-analysis Version 2; Biostat,
Inc. Englewood NJ, 2005).
RESULTS
The electronic and manual searches retrieved 1,350 citations. All
citations were screened and 38 full text articles were retrieved for
further assessment. Reasons to withdraw the unselected studies
included: no randomization, no valid data, absent of control group,
review works, etc. Five studies were excluded(18-20), since they were
either not randomized, controlled or were comparisons of medical
versus surgical treatment. The reasons for exclusion are detailed in
the figure 1. Three randomized trials met the criteria for inclusion(15-17).
No newer study could be considered during the last search perfor-
med in January 2011. A summary of the characteristics of the included
studies is displayed in table 1.
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SETTING AND PARTICIPANTS
The three selected studies(15-17) included trials with a total of 457
randomized participants. All participants had newly diagnosed
open-angle glaucoma with no prior surgical treatment.
MAIN OUTCOMES
The primary outcome measure in all the trials was the rate of failure
to maintain the IOP <21 mmHg at 12 months. Two trials assessed change
in visual acuity during the follow-up. Cataract surgery was reported in
two trials(16,17) and additional glaucoma surgery, as a consequence of
failure, was reported by all studies. Adverse events were observed
in the intervention group in all trials. As the description of these
adverse effects was different in each trial, we analyzed each com-
plication separately (Table 2).
SURGICAL FAILURE
The three studies reported IOP maintained <21 mmHg at 12
months follow-up as one of the outcomes. Surgical failure rates were
lower for the BRT/TREC arm (9/239 = 3.8%) compared to control
arms (38/218 =17.4%). The individual odds ratios ranged from 2.97
to 9.29, with a pooled odds ratio for all of the trials of 6.7 with a
95% CI of 3.2 to 14.3 (Figure 2). Since the heterogeneity test
showed no statistical significance (P=0.47), the pooling of the data
was considered valid. Ethnic subgroups analysis displayed a
tendency towards less surgical failure, but not significantly, in the
BRT/TREC arm comparing to control arm, in Caucasian patients
(P=0.055) (Figure 3).
IOP REDUCTION
At 12 months, the BRT/TREC group was associated with signi-
ficantly greater IOP reduction than TREC alone (difference in the
IOP reduction from baseline of 1.65 between groups, 95% CI: 0.61 -
2.68), as demonstrated in figure 4. The subgroups’ analysis accor-
ding to ethnic group revealed that the IOP reduction was greater
in Black patients than Caucasian patients in BRT/TREC arm. Black
patients showed significant mean difference in the IOP from base-
line (2.0 mmHg; 95% CI: 0.6 - 3.3, p=0.005), while Caucasian patients
presented no significant mean difference (1.2 mmHg; 95% CI: 0.32 -
2.8, P=0.120) (Figure 5).
POSTOPERATIVE COMPLICATIONS
All three studies reported postoperative adverse events as one
of the outcomes. No complication was described repeatedly in all
of these studies. Thus, each complication was analyzed when
described in more than one study. Endophthalmitis, uveitis and
suprachoroidal hemorrhage were reported in only one of these
studies (Table 2). No significant difference in the proportion of eachFigure 1. Flowchart of the studies’ selection according to QUOROM criteria.
Table 1. Characteristic of patients of the trials included in this meta-analysis
England(15) New Zealand(16) South Africa(17)
Variables Control BRT (750cGy) Control BRT (750 cGy) Control BRT (1000 cGy)
Type of Glaucoma
Primary open-angle glaucoma 22 37 31 34 120 113
Pseudo exfoliation 0 1 0 0  33  39
Other 0 1 0 0 03  12
Age 73 (67-78) 73 (66-79) 70.5 (50-86) 72.8 (56-86) 50-69 (50%)* 50-69 (57%)*
Ethnicity
Caucasian 22 38 31 34 0 0
Black 0 0 0 0 156 164
Gender
Male 12 (54%) 20 (51%) 17 (55%) 16 (47%) 97 (62.1%) 92 (56%)
Female 10 (46%) 19 (49%) 14 (45%) 18 (53%) 59 (38.0%) 72 (44%)
Preoperative medication
Beta block\Pilocarpine 22 (100%) 38 (99%) 1.84 (1-4)# 1.88 (1-3)# 69 (42.0%) 55 (35.0%)
No 0 001 (0.02%) 87 (55.7%) 109 (66.4%)
Preoperative IOP (mmHg) 24 (22-30) 24 (22-28) 22.51 (17-32) 23 (14-33) 25-34 (54.2%)* 25-34 (47.4%)*
BRT= trabeculectomy plus beta irradiation group; Control=  trabeculectomy group; IOP= intraocular pressure; *= range + (frequency of category); #= mean number of drugs + (range);
(15)= Rehman et al., 2002; (16)= Barnes et al., 2000; (17)= Kirwan et al., 2006.
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complication was observed between BRT/TREC arm and control arm:
hyphema (p=0.835), hypotony (P=0.541), shallow anterior chamber
(P=0.726), bleb leak (P=0.485) and choroidal effusion (P=0.473).
There was no significant difference in visual acuity reduction
(OR=0.84, 95% CI: 0.5 - 1.3, P=0.43) between the two arms. Moreo-
ver, no decrease in visual acuity was observed in either group during
the study period.
The BRT/TREC group experienced a higher incidence of cata-
ract considering the need for extraction than did the TREC group
(25/195 - 12.8% versus 9/190 - 4.7% participants), however this diffe-
rence was not statistically significant (OR=1.85, 95% CI: 0.82 - 4.16,
P=0.13).
DISCUSSION
The use of BRT in glaucoma surgery has been investigated by
several authors(6,14-20) but all reports included small numbers of
patients, and the irradiation tended to be used in mixed groups of
patients with poor prognosis. There are no convincing data from
these studies indicating that BRT improves the IOP control post-
trabeculectomy, which explains why this technique has not gained
popularity.
In our study, combining the results of three randomized trials
(457 patients), we were able to demonstrate a significant positive
adjunctive effect of BRT in eyes undergoing TREC. The mean
difference between the IOP reduction from baseline obtained in
BRT-treated eyes and the control group at one year follow-up was
1.64 mmHg (P=0.002).
We did not find any significant difference in the analysis of each
complication regarding radiotherapy adjunctive treatment. Howe-
ver, the radiation group experienced a higher incidence of cataract
requiring extraction than did the control group (12.8% versus 4.7%
respectively; P=0.13). We are not aware if this difference would be
significant with an increment of sample size.
The calculated amount of radiation reaching the germinal epi-
thelium of lenses in all trials was probably less than the minimum
dosage reported to cause cataract (200 cGy)(27,28). Radiation-induced
cataract has a characteristic pattern of cortical opacity, starting at
the site of application(29), which was not observed in the patients of
those studies.
A possible limitation of the present study could be related to
differences in the clinical characteristics of patients included in the
groups. Although Rehman et al.(15) and Barnes et al.(16) have com-
pared basically patients on maximal tolerated medical therapy, Kirwan
et al.(17) performed surgeries in both patients on maximal therapy
and those without previous treatment (Table 1). These details could
explain differences in the surgical results and represent a potential
heterogeneity, however a division in subgroups for statistical
purposes could be also a source of bias. Moreover, this analysis was
not possible due to the lack of detailed data(17) (Table 3).
Figure 2. Comparison of surgical failure rate at the of 12 months follow-up, between TREC and BRT/TREC arms.
(15)= Rehman et al., 2002; (16)= Barnes et al., 2000; (17)= Kirwan et al., 2006.
Table 2. Postoperative complications in the trials included in this meta-analysis
England(15) New Zealand(16) South Africa(17)
Control BRT (750 cGy) Control BRT (750 cGy) Control BRT (1000 cGy)
Hyphema 4 (18%) 9 (23.0%.) 15 (44.1%) 16 (51.6%) - -
Hypotony 2 (09%) 2 (25.0%) - - 2 (1.2%) 06 (0,3.6%)
Shallow anterior chamber        - - 06 (17.6%) 09 (29.0%) 3 (1.9%) 02 (0,1.2%)
Bleb leak 1 (05%) 2 (25.0%) 02 (05.8%) - -   -
Choroidal effusion 1 (05%) 1 (22.5%) 02 (05.8%) 05 (16.1%) - -
Endophthalmitis        - 1 (22.5%) - - - -
Uveitis        - - - - 4 (2.5%) 7 (04.2%)
Suprachoroidal hemorrage        - - - - 1 (0.6%) -
Cataract NA NA 04 (12.1%) 07 (24.1%) 5 (3.4%) 18 (11.9%)
BRT= trabeculectomy plus beta irradiation group; Control= trabeculectomy group; NA= not available; (15)= Rehman et al., 2002; (16)= Barnes et al., 2000; (17)= Kirwan et al., 2006.
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Figure 5. Comparison of the differences of mean IOP reductions between TREC and BRT/TREC arms, at the end of follow-up period, according to ethnic group.
(15)= Rehman et al., 2002; (16)= Barnes et al., 2000; (17)= Kirwan et al., 2006.
Figure 3. Comparison of surgical failure rate at the end of 12 months follow-up, between TREC and BRT/TREC arms, considering to ethnic groups.
(15)= Rehman et al., 2002; (16)= Barnes et al., 2000; (17)= Kirwan et al., 2006.
Figure 4. Comparison of the differences of mean IOP reductions between TREC and BRT/TREC arms, at the end of follow-up period.
(15)= Rehman et al., 2002; (16)= Barnes et al., 2000; (17)= Kirwan et al., 2006.
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The application of beta radiation is rapid and focal, both dose
and the area treated can be controlled with accuracy, which
reduces the risk of accidental over dosage. A customized applicator
is applied only to the desired area. Despite of these advantages of
beta radiation, most of glaucoma surgeons choose not to use this
procedure probably because the severe adverse events observed
in the postoperative period of adjuvant BRT in pterygium surgery.
However, we believe that the benefits and complications of the
ocular use of beta radiation are open to debate and further studies
are necessary.
A previous systematic review has shown similar results(21), howe-
ver it was based on an extra study, which is not a RCT and has not
been completely published yet(30).
In our analysis, a significant IOP reduction was observed in Black
patients (P=0.005), however there is only a trend towards a signifi-
cant difference for the IOP control in the Caucasian patients treated
by BRT (P=0.05). Although Black patients have shown an aggressive
healing response(31), this difference could be explained by sample
size of these trials, instead of a real difference due to ethnic sub-
groups. The necessary statistic power for these two studies(15,16) able
to detect a 10% (postulated) difference in the primary outcome,
considering the confidence intervals of 95%, was around 20-25%. In
this way, the small number of participants in these studies may
compromise the presented statistical analysis. For example, in
order to detect a 10% reduction in TREC failure, more than 250
surgeries would be required. Thus, further RCT with an enough
sample size should be performed to evaluate the benefits of the
BRT in Caucasian patients.
CONCLUSIONS
Our data suggest a significant impact on the outcomes of TREC
followed by BRT, mainly in Black patients. Perioperative application
of a single dose of BRT in the surgical site showed to be safe, with
no significant differences in the frequency of complication, at 12
months follow-up. Further studies are required to assess the im-
pact of BRT in TREC and to determine whether increasing dosage
and/or fractionating treatment could enhance the success of rou-
tine TREC. Thus, these presented data might be used to guide further
randomized clinical trial comparing MMC or 5-FU with adjuvant BRT
in glaucoma patients.
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